苹果酸法米替尼胶囊 | China Drugs ListFamitinib malate capsules | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
- 企业
- 江苏恒瑞医药股份有限公司Jiangsu Hengrui Pharmaceuticals Co., Ltd.
- 药品类型
- 化学药Chemical medicine
- 治疗领域
- 肿瘤科Oncology
- 公开来源记录的适应症
- 均需联合注射用卡瑞利珠单抗治疗复发或转移性宫颈癌：①既往含铂化疗失败且未接受过贝伐珠单抗；②经充分验证的检测方法确认PD-L1表达阳性（CPS≥1）的患者的一线治疗。Both uses require combination with camrelizumab for recurrent or metastatic cervical cancer: (1) after failure of platinum-based chemotherapy, without previous bevacizumab treatment; or (2) as first-line treatment of PD-L1-positive disease (CPS >=1), confirmed by a fully validated test.
- 适应症来源与口径
- 2026-07-21
- 说明书信息局限
- 已取得完整官方药品说明书。 中国大陆说明书。 生产商原始页面图像已按顺序保存。Complete official prescribing information obtained. Mainland China label. Original manufacturer page images have been preserved in order.
- 中国可获得性状态
- 已核实中国历史批准记录；尚未逐项核查每个产品目前是否持续上市销售。Historical Chinese approval verified; current continuous market availability has not been checked for every product.
- 海外状态
- 待逐一核查各市场。Market-by-market verification pending.
- 医保分类
- 已纳入国家医保（乙类）Included in national insurance (Category B)
- 医保版本
- 2025版；2026年1月1日起执行2025 edition; effective 1 January 2026
- 医保限制
- 限联合注射用卡瑞利珠单抗用于既往接受含铂化疗治疗失败但未接受过贝伐珠单抗治疗的复发或转移性宫颈癌患者。Restricted to use with camrelizumab for recurrent or metastatic cervical cancer after failure of platinum-based chemotherapy, without previous bevacizumab treatment.
- 医保期限
- 2026-01-01 至 2027-12-312026-01-01 to 2027-12-31
- 医保核查说明
- 按成分／剂型名称精确或标准化匹配。报销仍取决于剂型及目录所列支付限制。Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.